Logo
x

Search category

Subscribe Now

Takeda

Takeda and HUTCHMED Report EMA’s Validation of MAA for Fruquintinib to Treat Metastatic Colorectal Cancer

Takeda and HUTCHMED Report EMA’s Validation of MAA for Fruquintinib to Treat Metastatic Colorectal Cancer

  • July 25, 2023
Takeda Presents P-III Trial (ADVANCE-CIDP 1) Results of Hyqvia for Chronic Inflammatory Demyelinating Polyneuropathy at PNS 2023, Published in the JPNS

Takeda Presents P-III Trial (ADVANCE-CIDP 1) Results of Hyqvia for Chronic Inflammatory Demyelinating Polyneuropathy at PNS 2023,...

  • June 22, 2023
Takeda and HUTCHMED Reports P-III Study (FRESCO2) Results of Fruquintinib in the P-III Study (FRESCO-2) for Metastatic Colorectal Cancer

Takeda and HUTCHMED Reports P-III Study (FRESCO2) Results of Fruquintinib in the P-III Study (FRESCO-2) for Metastatic Colorectal...

  • June 16, 2023
Takeda and HUTCHMED's Fruquintinib Receives Priority Review from the US FDA to Treat Metastatic Colorectal Cancer

Takeda and HUTCHMED's Fruquintinib Receives Priority Review from the US FDA to Treat Metastatic Colorectal Cancer

  • May 26, 2023
Takeda Reports the US FDA Acceptance of BLA and Granted Priority Review of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura

Takeda Reports the US FDA Acceptance of BLA and Granted Priority Review of TAK-755 for Congenital Thrombotic Thrombocytopenic Purp...

  • May 17, 2023
Takeda Reports BLA Resubmission to the US FDA for Entyvio as a Maintenance Therapy for Ulcerative Colitis

Takeda Reports BLA Resubmission to the US FDA for Entyvio as a Maintenance Therapy for Ulcerative Colitis

  • April 28, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.